pH-responsive glucosamine anchored polydopamine coated mesoporous silica nanoparticles for delivery of Anderson-type polyoxomolybdate in breast cancer

Ramezani-Aliakbari, Maryam; Varshosaz, Jaleh; Mirian, Mina; Khodarahmi, Ghadamali; Rostami, Mahboubeh

doi:10.1080/02652048.2022.2096139

Cited by 10 publications

(4 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, another study that used a similar coating strategy to yield hybrid MSN@PDA also expanded the feasibility of this platform in terms of exploring its ability to intracellular delivery of both a hydrophilic and hydrophobic (fingolimod, FTY720) anti-cancer drug, as well as investigate the effect of particle shape on intracellular release [ 279 ]. In a very recent report, it has been synthesized a pH-responsive glucosamine anchored polydopamine coated MSN for delivery of Anderson-type polyoxomolybdate in breast cancer [ 160 ].…”

Section: Functionalization Of Msns With Biopolymersmentioning

confidence: 99%

Natural Biopolymers as Smart Coating Materials of Mesoporous Silica Nanoparticles for Drug Delivery

et al. 2023

View full text Add to dashboard Cite

In recent years, the functionalization of mesoporous silica nanoparticles (MSNs) with different types of responsive pore gatekeepers have shown great potential for the formulation of drug delivery systems (DDS) with minimal premature leakage and site-specific controlled release. New nanotechnological approaches have been developed with the objective of utilizing natural biopolymers as smart materials in drug delivery applications. Natural biopolymers are sensitive to various physicochemical and biological stimuli and are endowed with intrinsic biodegradability, biocompatibility, and low immunogenicity. Their use as biocompatible smart coatings has extensively been investigated in the last few years. This review summarizes the MSNs coating procedures with natural polysaccharides and protein-based biopolymers, focusing on their application as responsive materials to endogenous stimuli. Biopolymer-coated MSNs, which conjugate the nanocarrier features of mesoporous silica with the biocompatibility and controlled delivery provided by natural coatings, have shown promising therapeutic outcomes and the potential to emerge as valuable candidates for the selective treatment of various diseases.

show abstract

Section: Functionalization Of Msns With Biopolymersmentioning

confidence: 99%

Natural Biopolymers as Smart Coating Materials of Mesoporous Silica Nanoparticles for Drug Delivery

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The optimized anderson-type polyoxomolybdate NPs exhibited pH-dependent drug release, an average particle size of 195 nm, a zeta potential of −18.9 mV, and a 45% drug loading capacity. The targeted NPs demonstrated enhanced anticancer activity against MDA-MB-231 BC cell lines, with the highest cellular uptake and apoptosis . Therefore, MSNPs could be clinically successful nanocarriers.…”

Section: Therapeutic Interventions Involving Nanocarriers For Managem...mentioning

confidence: 99%

“…The targeted NPs demonstrated enhanced anticancer activity against MDA-MB-231 BC cell lines, with the highest cellular uptake and apoptosis. 107 Therefore, MSNPs could be clinically successful nanocarriers.…”

Section: Therapeutic Interventions Involving Nanocarriers For Managem...mentioning

confidence: 99%

Nanomedicine-Based Drug-Targeting in Breast Cancer: Pharmacokinetics, Clinical Progress, and Challenges

Rahman,

Afzal,

Ullah

et al. 2023

ACS Omega

View full text Add to dashboard Cite

Breast cancer (BC) is a malignant neoplasm that begins in the breast tissue. After skin cancer, BC is the second most common type of cancer in women. At the end of 2040, the number of newly diagnosed BC cases is projected to increase by over 40%, reaching approximately 3 million worldwide annually. The hormonal and chemotherapeutic approaches based on conventional formulations have inappropriate therapeutic effects and suboptimal pharmacokinetic responses with nonspecific targeting actions. To overcome such issues, the use of nanomedicines, including liposomes, nanoparticles, micelles, hybrid nanoparticles, etc., has gained wider attention in the treatment of BC. Smaller dimensional nanomedicine (especially 50–200 nm) exhibited improved in vivo effectiveness, such as better tissue penetration and more effective tumor suppression through enhanced retention and permeation, as well as active targeting of the drug. Additionally, nanotechnology, which further extended and developed theranostic nanomedicine by incorporating diagnostic and imaging agents in one platform, has been applied to BC. Furthermore, hybrid and theranostic nanomedicine has also been explored for gene delivery as anticancer therapeutics in BC. Moreover, the nanocarriers’ size, shape, surface charge, chemical compositions, and surface area play an important role in the nanocarriers’ stability, cellular absorption, cytotoxicity, cellular uptake, and toxicity. Additionally, nanomedicine clinical translation for managing BC remains a slow process. However, a few cases are being used clinically, and their progress with the current challenges is addressed in this Review. Therefore, this Review extensively discusses recent advancements in nanomedicine and its clinical challenges in BC.

show abstract

“…Nanoparticles may increase the concentration of drugs in the tumour site and keep them for a longer time. Specifically, mesoporous silica nanoparticles (MSN) can be designed to increase the penetration in certain tissues 18 , to be hidden from the immune system 19 and also to be responsive to different types of stimuli such as environmental pH 20 , 21 and redox conditions 22 , 23 . Besides their responsiveness, the nanoparticle surface functionalization permits the strategical pore closure to control the release and target the therapy to specific sites 24 .…”

Section: Introductionmentioning

confidence: 99%

Nanocomposite formulation for a sustained release of free drug and drug-loaded responsive nanoparticles: an approach for a local therapy of glioblastoma multiforme

Erthal

Shi

Sweeney

et al. 2023

Sci Rep

View full text Add to dashboard Cite

Malignant gliomas are a type of primary brain tumour that originates in glial cells. Among them, glioblastoma multiforme (GBM) is the most common and the most aggressive brain tumour in adults, classified as grade IV by the World Health Organization. The standard care for GBM, known as the Stupp protocol includes surgical resection followed by oral chemotherapy with temozolomide (TMZ). This treatment option provides a median survival prognosis of only 16–18 months to patients mainly due to tumour recurrence. Therefore, enhanced treatment options are urgently needed for this disease. Here we show the development, characterization, and in vitro and in vivo evaluation of a new composite material for local therapy of GBM post-surgery. We developed responsive nanoparticles that were loaded with paclitaxel (PTX), and that showed penetration in 3D spheroids and cell internalization. These nanoparticles were found to be cytotoxic in 2D (U-87 cells) and 3D (U-87 spheroids) models of GBM. The incorporation of these nanoparticles into a hydrogel facilitates their sustained release in time. Moreover, the formulation of this hydrogel containing PTX-loaded responsive nanoparticles and free TMZ was able to delay tumour recurrence in vivo after resection surgery. Therefore, our formulation represents a promising approach to develop combined local therapies against GBM using injectable hydrogels containing nanoparticles.

show abstract

pH-responsive glucosamine anchored polydopamine coated mesoporous silica nanoparticles for delivery of Anderson-type polyoxomolybdate in breast cancer

Cited by 10 publications

References 76 publications

Natural Biopolymers as Smart Coating Materials of Mesoporous Silica Nanoparticles for Drug Delivery

Natural Biopolymers as Smart Coating Materials of Mesoporous Silica Nanoparticles for Drug Delivery

Nanomedicine-Based Drug-Targeting in Breast Cancer: Pharmacokinetics, Clinical Progress, and Challenges

Nanocomposite formulation for a sustained release of free drug and drug-loaded responsive nanoparticles: an approach for a local therapy of glioblastoma multiforme

Contact Info

Product

Resources

About